TW330204B - Endothelin receptor antagonists - Google Patents

Endothelin receptor antagonists

Info

Publication number
TW330204B
TW330204B TW083106015A TW83106015A TW330204B TW 330204 B TW330204 B TW 330204B TW 083106015 A TW083106015 A TW 083106015A TW 83106015 A TW83106015 A TW 83106015A TW 330204 B TW330204 B TW 330204B
Authority
TW
Taiwan
Prior art keywords
hydrogen
ethyl
methoxy
carbonyl
yloxy
Prior art date
Application number
TW083106015A
Other languages
English (en)
Chinese (zh)
Inventor
Donovan Cousins Russell
Duncan Elliott John
Amparo Lago Maria
Dale Leber Jack
Elizabeth Peishoff Catherine
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of TW330204B publication Critical patent/TW330204B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30Unsaturated compounds
    • C07C62/34Unsaturated compounds containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW083106015A 1993-04-27 1994-07-01 Endothelin receptor antagonists TW330204B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6681893A 1993-04-27 1993-04-27

Publications (1)

Publication Number Publication Date
TW330204B true TW330204B (en) 1998-04-21

Family

ID=22071916

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083106015A TW330204B (en) 1993-04-27 1994-07-01 Endothelin receptor antagonists

Country Status (28)

Country Link
EP (1) EP0699069B9 (enExample)
JP (1) JP3346571B2 (enExample)
KR (1) KR100331667B1 (enExample)
CN (1) CN1129428C (enExample)
AP (1) AP573A (enExample)
AT (1) ATE213156T1 (enExample)
AU (1) AU682038B2 (enExample)
BR (1) BR9406572A (enExample)
CA (1) CA2160914A1 (enExample)
CZ (1) CZ291189B6 (enExample)
DE (1) DE69429861T2 (enExample)
DK (1) DK0699069T3 (enExample)
DZ (1) DZ1773A1 (enExample)
ES (1) ES2172535T3 (enExample)
FI (1) FI955103A7 (enExample)
HU (2) HU9503067D0 (enExample)
IL (1) IL109443A0 (enExample)
MA (1) MA23172A1 (enExample)
NO (1) NO313754B1 (enExample)
NZ (1) NZ266314A (enExample)
PL (1) PL175392B1 (enExample)
PT (1) PT699069E (enExample)
RU (1) RU2130920C1 (enExample)
SG (1) SG49667A1 (enExample)
SI (1) SI9400195B (enExample)
SK (1) SK130595A3 (enExample)
TW (1) TW330204B (enExample)
WO (1) WO1994025013A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075037A (en) * 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
JPH10501812A (ja) * 1994-06-20 1998-02-17 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗薬
WO1996020193A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation Compounds and methods
AU7677496A (en) * 1995-11-08 1997-05-29 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
ZA969363B (en) * 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
IL126175A (en) 1996-04-04 2003-05-29 Banyu Pharma Co Ltd Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
AU3867997A (en) 1996-08-27 1998-03-19 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
JP2002511442A (ja) * 1998-04-09 2002-04-16 メルク エンド カムパニー インコーポレーテッド ホスフェート介在の環化
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
NZ586285A (en) 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
US7423176B2 (en) 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
WO2006066748A1 (en) 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof as 5-ht antagonists
US20100040666A1 (en) * 2005-06-24 2010-02-18 Hiroshi Azuma Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent
JP4989648B2 (ja) 2005-08-03 2012-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗癌剤として有用なイルジン類似体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737455A (en) * 1971-01-21 1973-06-05 Merck & Co Inc Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof
FI942059A7 (fi) * 1991-11-05 1994-07-04 Smithkline Beecham Corp Endoteliinireseptoreiden antagonisteja

Also Published As

Publication number Publication date
DZ1773A1 (fr) 2002-02-17
PL175392B1 (pl) 1998-12-31
AP573A (en) 1997-01-30
FI955103A0 (fi) 1995-10-26
WO1994025013A1 (en) 1994-11-10
NO954291D0 (no) 1995-10-26
AU682038B2 (en) 1997-09-18
CZ283595A3 (en) 1996-03-13
SK130595A3 (en) 1996-06-05
DE69429861D1 (de) 2002-03-21
DK0699069T3 (da) 2002-05-27
HU9503067D0 (en) 1995-12-28
CN1129428C (zh) 2003-12-03
RU2130920C1 (ru) 1999-05-27
NZ266314A (en) 1998-10-28
CN1124923A (zh) 1996-06-19
PT699069E (pt) 2002-07-31
SG49667A1 (en) 1998-06-15
EP0699069B9 (en) 2003-10-22
NO954291L (no) 1995-12-21
EP0699069B1 (en) 2002-02-13
NO313754B1 (no) 2002-11-25
FI955103L (fi) 1995-10-26
SI9400195A (en) 1994-12-31
HU9501931D0 (en) 1995-09-28
MA23172A1 (fr) 1994-12-31
FI955103A7 (fi) 1995-10-26
EP0699069A1 (en) 1996-03-06
CZ291189B6 (cs) 2003-01-15
DE69429861T2 (de) 2002-09-19
IL109443A0 (en) 1994-07-31
HK1012252A1 (en) 1999-07-30
JP3346571B2 (ja) 2002-11-18
ATE213156T1 (de) 2002-02-15
CA2160914A1 (en) 1994-11-10
HUT73763A (en) 1996-09-30
PL311272A1 (en) 1996-02-05
JPH08510211A (ja) 1996-10-29
KR100331667B1 (ko) 2002-11-08
AP9400636A0 (en) 1994-04-30
EP0699069A4 (enExample) 1996-04-03
ES2172535T3 (es) 2002-10-01
BR9406572A (pt) 1996-01-30
SI9400195B (sl) 2003-10-31
AU6775094A (en) 1994-11-21

Similar Documents

Publication Publication Date Title
TW330204B (en) Endothelin receptor antagonists
CA2098568A1 (en) Metal alkoxides
BG104670A (en) 4-(2-keto-1-benzimidazolinyl)piperidinne compounds as orl1-receptor agonists
GB2270075B (en) Substituted 2-phenyl-3-methoxypropenoate fungicides
AU5571190A (en) Retroviral protease inhibiting compounds
AU2534295A (en) Gastrin and cck antagonists
AU1200695A (en) 4,5-diaryloxazole derivatives
GR3018543T3 (en) Process for the preparation of baccatin iii and 10-deacetyl baccatin iii derivatives
ES2122258T3 (es) 4-azaesteroides 15 sustituidos.
CA2306782A1 (en) Isoquinolines as urokinase inhibitors
CA2152817A1 (en) Novel Pyridone Carboxylic Acid Derivatives
NO981393D0 (no) Guanidinoproteasehemmere
GB9123967D0 (en) New compound and its preparation
JO2065B1 (en) Tri-azin compounds
BG101940A (en) New taxoids, their preparation and pharmaceutical compositions containing them
EP1099690A4 (en) MONOCYCLIC BETA LACTAM COMPOUNDS AND CHYMASE INHIBITORS THAT CONTAIN THEM
NO933837L (no) 4-aryl-3-(heteroarylureido)kinolin-derivater
EP1270569A4 (en) SUBSTITUTED TRYPTOPHAN DERIVATIVES
WO1993018173A3 (en) Cd4 binding agents and inhibitors of collagenase and protein kinase c
IL113899A (en) Fungicidal compositions comprising oxime ether carboxylic esters 1-(2-cyano-2-methoxyiminoacetyl)-3-ethylurea and optionally a dithiocarbamate
GB2333294A (en) Cytokine production inhibitors
MY116430A (en) Substituted oximes as neurokinin antagonists
AU751914C (en) Amine derivatives and process for producing the same
EP0739893A4 (enExample)
MY131175A (en) Heterocyclic compounds

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees